Breaking News

Antheia Secures Additional Funding from HHS to Onshore Supply Chains

U.S. government fortifies commitment to advanced manufacturing technology for the domestic production of essential medicines.

Author Image

By: Charlie Sternberg

Associate Editor

Antheia, a biosynthesis company delivering pharmaceutical manufacturing and innovation, has expanded the scope of its second project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), securing an additional $9 million. The additional funds bring the total project investment to $21 million directly supporting the company’s efforts to build resilient, domestic pharmaceutical supply chains.  The award, funded by the U.S. Department of Health and Human...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters